Bellicum Pharmaceuticals (NASDAQ:BLCM) Stock Crosses Above Fifty Day Moving Average of $0.08

Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.08 and traded as high as $0.09. Bellicum Pharmaceuticals shares last traded at $0.07, with a volume of 6,000 shares.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Bellicum Pharmaceuticals in a report on Tuesday. They issued a “sell” rating for the company.

Bellicum Pharmaceuticals Stock Down 6.6 %

The business has a fifty day moving average price of $0.08 and a 200 day moving average price of $0.14.

Hedge Funds Weigh In On Bellicum Pharmaceuticals

An institutional investor recently bought a new position in Bellicum Pharmaceuticals stock. HRT Financial LP bought a new stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned about 0.42% of Bellicum Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 4.93% of the company’s stock.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.